MX2012007397A - Composiciones y metodos para reducir la presion intraocular. - Google Patents

Composiciones y metodos para reducir la presion intraocular.

Info

Publication number
MX2012007397A
MX2012007397A MX2012007397A MX2012007397A MX2012007397A MX 2012007397 A MX2012007397 A MX 2012007397A MX 2012007397 A MX2012007397 A MX 2012007397A MX 2012007397 A MX2012007397 A MX 2012007397A MX 2012007397 A MX2012007397 A MX 2012007397A
Authority
MX
Mexico
Prior art keywords
lowering intraocular
pres sure
triple combination
iop
intraocular pres
Prior art date
Application number
MX2012007397A
Other languages
English (en)
Inventor
Chetan P Pujara
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43743470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012007397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2012007397A publication Critical patent/MX2012007397A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen composiciones para reducir la presión intraocular (IOP) de un ojo, que comprenden una combinación de agentes reductores de la IOP, bimatoprost, brimonidina y timolol. Además, se describen métodos para reducir la IOP en el ojo de un sujeto.
MX2012007397A 2009-12-22 2010-12-21 Composiciones y metodos para reducir la presion intraocular. MX2012007397A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28893609P 2009-12-22 2009-12-22
US36174910P 2010-07-06 2010-07-06
PCT/US2010/061563 WO2011087790A1 (en) 2009-12-22 2010-12-21 Triple combination for lowering intraocular pres sure

Publications (1)

Publication Number Publication Date
MX2012007397A true MX2012007397A (es) 2012-08-15

Family

ID=43743470

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007397A MX2012007397A (es) 2009-12-22 2010-12-21 Composiciones y metodos para reducir la presion intraocular.

Country Status (15)

Country Link
US (1) US20130116254A1 (es)
CN (1) CN102695498A (es)
AR (1) AR079696A1 (es)
BR (1) BR112012017319A2 (es)
CL (1) CL2012001736A1 (es)
CO (1) CO6592061A2 (es)
CR (1) CR20120360A (es)
EC (1) ECSP12012033A (es)
GT (1) GT201200213A (es)
IN (1) IN2012DN06416A (es)
MX (1) MX2012007397A (es)
NI (1) NI201200112A (es)
PE (2) PE20121468A1 (es)
TW (1) TW201143773A (es)
WO (1) WO2011087790A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
TR201818754T4 (tr) 2010-07-29 2019-01-21 Allergan Inc Koruyucu içermeyen Brimonidin Ve Timolol Çözeltileri
US9248135B2 (en) 2012-04-24 2016-02-02 Allergan, Inc. Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
EP4420726A3 (en) * 2015-03-19 2024-11-13 Allergan, Inc. Fixed dose combination of bromonidine and timolol
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统
US12064440B2 (en) * 2022-03-21 2024-08-20 Somerset Therapeutics, Llc Ophthalmic gel compositions of bimatoprost and timolol and associated methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution

Also Published As

Publication number Publication date
CO6592061A2 (es) 2013-01-02
PE20121468A1 (es) 2012-10-28
CN102695498A (zh) 2012-09-26
BR112012017319A2 (pt) 2016-04-19
CR20120360A (es) 2012-07-30
AR079696A1 (es) 2012-02-15
GT201200213A (es) 2014-08-29
PE20160904A1 (es) 2016-09-16
NI201200112A (es) 2013-04-09
CL2012001736A1 (es) 2012-10-12
US20130116254A1 (en) 2013-05-09
WO2011087790A1 (en) 2011-07-21
ECSP12012033A (es) 2012-10-30
IN2012DN06416A (es) 2015-10-09
TW201143773A (en) 2011-12-16

Similar Documents

Publication Publication Date Title
MX2012007397A (es) Composiciones y metodos para reducir la presion intraocular.
MY159244A (en) Method of reducing intraocular pressure in humans
EP3542629A3 (en) Dithiol compounds, derivatives, and uses therefor
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
MX2012003759A (es) Metodos y composiciones para tratamiento de fibrosis ocular.
PH12014500179A1 (en) Fixed dose combination of bimatoprost and brimonidine
MX2011008296A (es) Metodos y composiciones para el tratamiento de neovascularizacion.
WO2012016000A3 (en) Preservative free brimonidine and timolol solutions
WO2012015998A3 (en) Preservative free bimatoprost and timolol solutions
MX2012012941A (es) Nuevas composiciones oftalmicas.
EP4420726A3 (en) Fixed dose combination of bromonidine and timolol
WO2006062731A8 (en) Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
PH12012501320A1 (en) Combination, kit and method of reducing intraocular pressure
MX2007007614A (es) Agente preventivo o terapeutico para glaucoma.
WO2012015996A3 (en) Preservative free bimatoprost solutions
WO2011029102A3 (en) Cd117+cells and uses thereof
MX2010009814A (es) Compuestos con vitamina d y metodos para reducir la hipertension ocular.
WO2010040054A3 (en) Methods for suppressing toll-like receptor activity
WO2011054804A3 (en) Skin care compositions comprising phenoxyalkyl amines
WO2010046865A3 (en) Ophthalmic administration of a composition including brimonidine as a mist
WO2012024419A3 (en) Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
MX2012005447A (es) Combinacion farmacéutica de compuesto de prostaglandina y nsaid (medicamentos antiinflamantorios no esteroideos) para el tratamiento de glaucoma e hipertensión ocular.
WO2006007227A3 (en) Abnormal cannabidiols for lowering intraocular pressure
WO2008024846A3 (en) Brimonidine and timolol compositions
WO2011027365A3 (en) Ophthalmic compositions containing dorzolamide, timolol and brimonidine

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration